文献速递免疫规划妇幼与学校卫生卫生政策与健康促进

加拿大孕妇及产后人群对孕期呼吸道合胞病毒疫苗接种与婴儿单克隆抗体的接受度及偏好

Acceptance and preference between respiratory syncytial virus vaccination during pregnancy and infant monoclonal antibody among pregnant and postpartum persons in Canada.
PubMed 文献 · Vaccine · 2025-02-06

2023年9月至2024年3月,在COVERED全国前瞻性队列中开展网络横断面调查,纳入2023年怀孕且≥19岁者723人。79%愿接受至少一种RSV免疫策略,77%接受孕期接种、55%接受婴儿单克隆抗体,79%偏好孕期接种。接受孕期RSV疫苗的预测因素包括孕期接受Tdap和COVID-19疫苗及将RSV列为高优先级。

要点

  • 723名参与者中77%愿接受孕期RSV疫苗,55%愿接受婴儿单克隆抗体
  • 79%偏好孕期接种,4.4%偏好婴儿单克隆抗体,14%无偏好
  • 孕期接受Tdap和COVID-19疫苗及将RSV列为高优先级与接受RSV疫苗相关

核心结论

  • 在此全国调查中,超过三分之二参与者愿接受RSV疫苗,超过一半愿接受单克隆抗体;若可选择,绝大多数偏好孕期接种而非单克隆抗体,这些偏好应在制定政策时考虑并可能影响成本效用分析。

研究设计与样本

  • 2023年9月至2024年3月,在COVERED全国前瞻性队列研究内完成网络横断面调查,纳入2023年怀孕且≥19岁者,共723人完成RSV调查模块,其中50.3%(n=364)当时怀孕。

主要发现

  • 79%(n=568)愿接受至少一种RSV免疫策略,77%(n=559)愿接受孕期RSV接种,55%(n=396)愿接受婴儿单克隆抗体。
  • 79%(n=567)偏好孕期接种,4.4%(n=32)偏好婴儿单克隆抗体,14%(n=98)无偏好。
  • 疫苗优先级评分中Tdap最高(51%),其次RSV(17%)、COVID-19(14%)、乙型肝炎(11%)、流感(7%)。
  • 接受孕期RSV疫苗的预测因素包括孕期接受Tdap疫苗(p<0.001)和COVID-19疫苗(p=0.006)以及将RSV列为孕期疫苗高优先级(p=0.006)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vaccination during pregnancy and infant monoclonal antibodies (mAb) were recently approved to prevent respiratory syncytial virus (RSV) disease in infants. Our study aims to describe self-reported attitudes and preferences between vaccination during pregnancy and infant mAb for this indication. METHODS: From September 2023-March 2024, we completed a web-based, cross-sectional survey within the COVERED national prospective cohort study. Individuals who became pregnant in 2023 and were ≥ 19 years of age were included. We assessed demographics and general vaccination attitudes within and outside pregnancy, as well as attitudes toward newly licensed RSV products (i.e., vaccine during pregnancy, infant mAb), that were not yet available. Univariate and multivariate analysis was completed to identify predictors of accepting RSV immunization during pregnancy. RESULTS: A total of 723 participants completed the RSV survey module, of which 50.3 % (n = 364) were currently pregnant. Among all participants, 79 % (n = 568) would accept at least one of the RSV immunization strategies; 77 % (n = 559) would accept RSV vaccination during pregnancy and 55 % (n = 396) would accept infant mAb. Vaccination during pregnancy was preferred by 79 % (n = 567) of participants, infant mAb were preferred by 4.4 % (n = 32), and 14 % (n = 98) indicated no preference. Participants rated Tdap vaccination as the highest priority (51 %) followed by RSV (17 %), COVID-19 (14 %), hepatitis B (11 %), and influenza (7 %). Predictors of accepting RSV vaccine during pregnancy included acceptance of Tdap and COVID-19 vaccines during pregnancy (p < 0.001 and p = 0.006, respectively) and ranking RSV as a high priority among pregnancy vaccines (p = 0.006). CONCLUSION: In this national survey, more than two thirds of participants would accept the RSV vaccine while more than half would accept mAb. If given a choice, the vast majority preferred vaccination during pregnancy over mAb. These preferences should be considered when drafting policies and could influence cost-utility analyses.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. McClymont E, Wong JMH, Forward L, et al. Acceptance and preference between respiratory syncytial virus vaccination during pregnancy and infant monoclonal antibody among pregnant and postpartum persons in Canada. Vaccine. 2025. PMID: 39919449. doi:10.1016/j.vaccine.2025.126818

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。